Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30138547 | 0.92 | ADORA1 (0.39) | ADORA1ADORA2AADORA2BADORA3PRKAG1 | |
| SCHEMBL19859764 | 0.92 | ADORA1 (0.39) | ADORA1ADORA2AADORA2BADORA3PRKAG1 | |
| SCHEMBL19859850 | 0.91 | TYMP (0.39) | TYMPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL21046386 | 0.88 | TYMP (0.34) | TYMPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL21046369 | 0.88 | TYMP (0.37) | TYMPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL21046368 | 0.84 | TYMP (0.38) | TYMPADORA2AADORA2BNT5E | |
| SCHEMBL19859742 | 0.82 | NT5E (0.36) | ADORA1ADORA2AADORA2BADORA3NT5E | |
| SCHEMBL19859716 | 0.81 | NT5E (0.36) | ADORA1ADORA2AADORA2BADORA3NT5E | |
| SCHEMBL19859357 | 0.81 | ADORA3 (0.44) | ADORA1ADORA2AADORA2BADORA3PRKAG1 | |
| SCHEMBL19859365 | 0.81 | ADORA3 (0.51) | ADORA1ADORA2AADORA2BADORA3PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497111-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031818-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TYMP 11/4885ADORA1 114/4885ADORA2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.